The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PLRX | -86.77% | -92.39% | -40.22% | -92% |
| S&P | +16.9% | +95.99% | +14.39% | +117% |
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.45M | 28.1% |
| Market Cap | $71.21M | -89.0% |
| Market Cap / Employee | $0.42M | 0.0% |
| Employees | 171 | 8.2% |
| Net Income | -$43.30M | 22.5% |
| EBITDA | -$45.15M | 24.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $86.82M | 8.0% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $59.15M | -1.6% |
| Short Term Debt | $1.23M | 1150.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -52.83% | -17.8% |
| Return On Invested Capital | -38.24% | -11.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$40.72M | 12.5% |
| Operating Free Cash Flow | -$40.60M | 10.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.73 | 2.32 | 0.27 | 0.28 | -81.32% |
| Price to Sales | 686.63 | 3615.71 | - | ||
| Price to Tangible Book Value | 1.73 | 2.32 | 0.27 | 0.28 | -81.32% |
| Enterprise Value to EBITDA | -5.47 | -9.57 | 2.78 | 2.91 | -164.00% |
| Return on Equity | -47.5% | -54.1% | -63.2% | -67.6% | 68.64% |
| Total Debt | $60.21M | $60.19M | $60.17M | $60.38M | 0.25% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
